MedTrace Logo

FT596 in Combination With R-CHOP in Subjects With B-Cell Lymphoma

NCT05934097 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-07-06

No results posted yet for this study

Summary

This is a Phase I study of FT596 in combination with two different schedules (standard or alternate) of R-CHOP in subjects with B-cell lymphoma who are previously untreated or have received no more than one prior line of treatment. The study will consist of a dose-escalation stage followed by a dose-expansion stage.

Conditions

Interventions

DRUG

FT596

Dosing to be initiated at a dose no higher than highest tolerable dose in study FT596-101, intravenously

DRUG

Cyclophosphamide

750 mg/m\^2 intravenously

DRUG

Doxorubicin

50 mg/m\^2 intravenously

DRUG

Vincristine

1.4 mg/m\^2 (maximum dose 2 mg) intravenously

DRUG

Prednisone

100 mg orally

DRUG

Rituximab

375 mg/m\^2 intravenously

DRUG

Bendamustine

90 mg/m\^2 IV infusion

Sponsors & Collaborators

Principal Investigators

  • Fate Trial Disclosure · Fate Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-12-31
Primary Completion
2026-05-31
Completion
2039-05-31
FDA Drug
Yes

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05934097 on ClinicalTrials.gov